trending Market Intelligence /marketintelligence/en/news-insights/trending/72MDez_qnIewE0Zf1FXGBg2 content esgSubNav
In This List

Becton Dickinson fiscal Q3 earnings up 5.8% YOY

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Becton Dickinson fiscal Q3 earnings up 5.8% YOY

Becton Dickinson and Co. said its adjusted EPS for the fiscal third quarter ended June 30 rose 5.8% to $3.08 from $2.91 a year earlier.

The S&P Global Market Intelligence consensus normalized EPS estimate for the fiscal quarter was $3.06.

Revenue for the quarter was $4.35 billion, up 1.7% year over year from $4.28 billion. Research and development expenses for the three-month period were up 2.1% to $282 million.

On a GAAP basis, the Franklin Lakes, N.J.-based medical device company booked a fiscal third-quarter net income applicable to common shareholders of $413 million, or $1.51 per share, down 25.7% from $556 million, or $2.03 per share, in the year-ago period.

Becton Dickinson reaffirmed its revenue and earnings guidance for the full year. The company continues to expect fiscal 2019 revenues to increase by 8% to 9%, and it expects adjusted EPS to be between $11.65 and $11.75.

The S&P Global Market Intelligence consensus normalized EPS estimate for the full fiscal year is $11.70.

Becton Dickinson develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products worldwide.